Respiratory syncytial virus (RSV) immune globulin intravenous therapy for RSV lower respiratory tract infection in infants and young children at high risk for severe RSV infections: Respiratory Syncytial Virus Immune Globulin Study Group
Abstract
RSVIG treatment was safe but not efficacious in the treatment of children with bronchopulmonary dysplasia, congenital heart disease, or premature gestation who were hospitalized with RSV LRI.
Keywords
National Center for Biotechnology Information
NCBI
NLM
MEDLINE
humans
pubmed abstract
nih
national institutes of health
national library of medicine
treatment outcome
research support
u.s. gov't
Child
Infant
newborn
P.H.S.
preschool
risk factors
Clinical Trial
Randomized Controlled Trial
Double-Blind Method
follow-up studies
immunoglobulins
intravenous / therapeutic use*
comment
pneumonia
hospitalization
human / immunology
respiratory syncytial virus infections / therapy*
respiratory syncytial virus
heart defects
respiratory syncytial virus infections / complications
viral / virology
premature
viral / complications
bronchiolitis / virology
viral / therapy*
w c gruber
pmid:9041304
doi:10.1542/peds.99.3.454
w j rodriguez
a a kramer
bronchiolitis / complications
bronchiolitis / therapy*
bronchopulmonary dysplasia / complications
congenital / complications
Access
Citation
ID:
118752
References
Blockchain Verification
Account:
NFT Contract Address:
0x95644003c57E6F55A65596E3D9Eac6813e3566dA
Article ID:
118752
Unique Identifier:
Network:
Scimatic Chain (ID: 481)
Loading...
Blockchain Readiness Checklist
Authors
Abstract
Journal Name
Year
Title
Creates 1,000,000 NFT tokens for this article
Token Features:
- ERC-1155 Standard NFT
- 1 Million Supply per Article
- Transferable via MetaMask
- Permanent Blockchain Record
Scan with Saymatik Web3.0 Wallet